Abbott Launches US Pivotal Trial Of TriClip Transcatheter Tricuspid Valve Repair System

The 700-patient TRILUMINATE Pivotal will compare Abbott’s TriClip transcatheter tricuspid valve repair device to medical therapy alone. TriClip is a tricuspid version of the company’s successful MitraClip transcatheter mitral valve repair device.

BEIJING, CHINA- JULY 15, 2017: Abbott sign; Abbott Laboratories, founded in 1888, is a health care company that serves worldwide. It has more than 20 billon USD in revenue last year. - Image
• Source: shutterstock.com

[Editor's Note: Important medical device trial presentations are tracked by Informa’s MeddevicetrackerClick here to request a demonstration. For an archive of previous articles on clinical trials, visit the Clinical Trials page.]

The TRILUMINATE Pivotal trial of Abbott Laboratories Inc.'s TriClip transcatheter tricuspid valve repair system for treating severe tricuspid regurgitation has begun with the first patients being treated at...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D